Pharmafile Logo
Pharmafocus logo
Advanced Search

Crohn’s disease

Showing 15 posts of 28 posts found.

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023
Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …

News

Research shows neonatal stem cells could be used as treatment for Crohn’s disease

July 31, 2023
Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal

Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

May 11, 2020
Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …

News
janssen_latest_logo_on_sign_closer

Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease

February 18, 2020
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment …

News
entrance_takeda_i020_v1

Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease

February 17, 2020
Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease

July 23, 2019
Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

News
takeda_global_hq

Takeda scores Japanese Entyvio approval in Crohn’s disease

May 22, 2019
Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma

Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …

News

Stem cells could ‘reset’ immune system in Crohn’s disease patients

August 8, 2018
Research and Development Crohn’s disease, Stem cells, crohn's disease, trials

A clinical trial led by researchers at Queen Mary University, London is looking into ways in which patients with Crohn’s …

News
european_commission_web

Takeda and TiGenix’s Alofisel becomes first donor-derived stem cell therapy approved in Europe

March 26, 2018
Sales and Marketing Crohn’s disease, EU, Europe, European Commission, Takeda, TiGenix, crohn's disease, pharma

The European Commission has awarded approval to Takeda and TiGenix’s allogeneic expanded adipose-derived stem cell (eASC) therapy Alofisel (darvadstrocel) for …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal

October 30, 2017
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …

News
pfizer-building-logo1web

Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says

October 30, 2017
Research and Development, Sales and Marketing Crohn’s disease, Pfizer, Remicade, crohn's disease, inflectra, pharma

Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …

News

NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara

May 3, 2017
Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease

Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …

News
celgene_1_02

Celgene trial displays promising results for Crohn’s disease alternative treatment

October 17, 2016
Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial

Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …

News
medimmune

AstraZeneca agrees $250 million licensing agreement with Allergan

October 3, 2016
Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease

Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …

News
janssen_latest_logo_on_sign

Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials

May 26, 2016
Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelara, crohn's disease, drug trial

Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials.  The company said a significant …

News

Latest content

Regeneron and Mammoth Biosciences announce CRISPR collaboration

April 26, 2024

ANGLE signs commercial agreement with AstraZeneca

April 26, 2024

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024